公开(公告)号：WO2019141972A1

公开(公告)日：2019-07-25

申请号：PCT/GB2019/050097

申请日：2019-01-15

申请人： GLOBACHEM NV

发明人： URCH, Christopher John ,  JACKSON, Victoria, Elizabeth ,  JORDAN, Linda ,  BAETZNER, Effi ,  MCGAW, Oliver, James, Stephen

IPC分类号： C07D401/04 ,  A01N43/52 ,  A01N43/54 ,  A01N43/58 ,  A01N43/64 ,  C07D235/08 ,  C07D403/04

CPC分类号： C07D235/08 ,  A01N43/52 ,  A01N43/54 ,  A01N43/58 ,  A01N43/64 ,  A01N43/647 ,  C07D401/04 ,  C07D403/04

摘要： The present invention relates to benzimidazole and benzotriazole compounds which are of use in the field of agriculture as fungicides.

公开(公告)号：WO2019126730A1

公开(公告)日：2019-06-27

申请号：PCT/US2018/067261

申请日：2018-12-21

申请人： PETRA PHARMA CORPORATION

发明人： KESICKI, Edward A. ,  LINDSTRÖM, Johan ,  PERSSON, Lars Boukharta ,  VIKLUND, Jenny ,  FORSBLOM, Rickard ,  GINMAN, Tobias ,  HICKEY, Eugene R. ,  DAHLGREN, Markus K. ,  GERASYUTO, Aleksey I.

IPC分类号： C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D417/14 ,  C07D471/04 ,  C07D491/04 ,  C07D207/24 ,  C07D498/04 ,  C07D498/14 ,  C07D515/14 ,  C07D519/00 ,  C07F5/04 ,  C07D213/61 ,  A61K31/405 ,  A61P35/00

CPC分类号： C07D213/61 ,  A61P35/00 ,  C07D207/24 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D417/14 ,  C07D471/04 ,  C07D491/04 ,  C07D498/04 ,  C07D498/14 ,  C07D515/14 ,  C07D519/00 ,  C07F5/04

摘要： The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I); where A1, A2, G, R1, R2, R3, R4, and W are described herein.

公开(公告)号：WO2019126098A1

公开(公告)日：2019-06-27

申请号：PCT/US2018/066127

申请日：2018-12-18

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： CHENG, Peter Tai Wah ,  LI, Jun ,  SHI, Yan ,  WANG, Ying ,  ZHANG, Hao ,  KENNEDY, Lawrence J. ,  WALKER, Steven J. ,  REDDIGUNTA, Ramesh Babu

IPC分类号： C07D231/12 ,  C07D401/04 ,  C07D403/04 ,  A61K31/415 ,  A61K31/4427 ,  A61K31/496 ,  A61P43/00

CPC分类号： C07D401/04 ,  C07D231/12 ,  C07D403/04

摘要： The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：WO2019126081A1

公开(公告)日：2019-06-27

申请号：PCT/US2018/066106

申请日：2018-12-18

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： DYCKMAN, Alaric J. ,  DODD, Dharmpal S. ,  MUSSARI, Christopher P. ,  SHERWOOD, Trevor C. ,  HAQUE, Tasir Shamsul ,  POSY, Shoshana L. ,  KUMAR, Sreekantha Ratna ,  PASUNOORI, Laxman ,  HEGDE, Subramanya ,  ANUMULA, Rushith Kumar

IPC分类号： C07D401/14 ,  C07D405/14 ,  C07D401/04 ,  C07D401/12 ,  C07D403/10 ,  C07D403/14 ,  C07D405/12 ,  C07D417/12 ,  C07D417/14 ,  C07D453/02 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D209/12 ,  A61K31/407 ,  A61P37/00

CPC分类号： C07D487/04 ,  C07D209/12 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  C07D417/14 ,  C07D453/02 ,  C07D471/04 ,  C07D471/10 ,  C07D487/08

摘要： N-oxides, or salts thereof, wherein G, L 2 , R 1 , R 5 , R 9 , R 10 , and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：WO2019121649A1

公开(公告)日：2019-06-27

申请号：PCT/EP2018/085444

申请日：2018-12-18

申请人： SIEGFRIED AG ,  CONTRAF-NICOTEX-TOBACCO GMBH

发明人： WEBER, Beat ,  PAN, Ben

IPC分类号： C07D401/04 ,  A61K31/465 ,  A61P25/34

CPC分类号： C07D401/04 ,  A61P25/34

摘要： The present invention relates to a method of separating racemic nicotine of Formula (l-a) as a mixture of the (R)- and (S)-enantiomers into the enantiomerically pure (S)- and (R)-nicotine represented by Formula (l-b) and (l-c), by adding a mixture of the L- and the D-enantiomer of a O,O'-disubstituted tartaric acid, wherein the molar ratio of the L- to the D-enantiomer is from 80:20 to 95:5, and obtaining the (S)-nicotine of formula (l-b), or by adding O,O'-dibenzoyl-D-tartaric acid and obtaining the (R)-nicotine of formula (l-c).

公开(公告)号：WO2019104011A1

公开(公告)日：2019-05-31

申请号：PCT/US2018/061965

申请日：2018-11-20

申请人： BIOMARIN PHARMACEUTICAL INC.

发明人： WANG, Bing

IPC分类号： C07D401/14 ,  C07D401/04 ,  C07D401/06 ,  C07D417/14 ,  C07D451/04 ,  A61P25/00 ,  A61K31/496

CPC分类号： C07D401/04 ,  A61P25/00 ,  C07D401/06 ,  C07D401/14 ,  C07D417/14 ,  C07D451/04

摘要： Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

公开(公告)号：WO2019097282A1

公开(公告)日：2019-05-23

申请号：PCT/IB2017/057247

申请日：2017-11-20

申请人： CELON PHARMA S.A. ,  UNIWERSYTET JAGIELLONSKI ,  INSTYTUT FARMAKOLOGII POLSKIEJ AKADEMII NAUK

发明人： KAMINSKI, Krzysztof ,  GRYCHOWSKA, Katarzyna ,  CANALE, Vittorio ,  BOJARSKI, Andrzej J. ,  SATALA, Grzegorz ,  LENDA, Tomasz ,  POPIK, Piotr ,  MATLOKA, Mikolaj ,  DUBIEL, Krzysztof ,  MOSZCZYNSKI-PETKOWSKI, Rafal ,  PIECZYKOLAN, Jerzy ,  WIECZOREK, Maciej ,  ZAJDEL, Pawel

IPC分类号： C07D403/12 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D409/12 ,  C07D413/04 ,  C07D487/08 ,  C07D209/44 ,  A61P25/28 ,  A61K31/4035

CPC分类号： C07D209/44 ,  A61K31/4035 ,  A61K31/454 ,  A61K31/496 ,  A61K31/4995 ,  A61K31/5377 ,  A61K31/5513 ,  A61K31/554 ,  A61P25/28 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D409/12 ,  C07D413/04 ,  C07D487/08

摘要： A compound of the formula (I) wherein R 1 represents hydrogen atom and R 2 represents moiety of the formula G1, or R 1 and R 2 are connected with each other to form with nitrogen atom to which they are attached a moiety of the formula G2; A is selected from the group consisting of phenyl substituted with one or two substituents selected from the group consisting of halogen atom, straight or branched C1- C4 alkyl, C1-C2 alkoxyl, CF 3 , CN, and -OCF 3 , naphthyl, quinolinyl, thienyl, thienyl substituted with halogen atom, and pyridyl; X is selected from the group consisting of -NR 4 , -0-, and -CHN(R 5 ) 2 ; R 3 is selected from the group consisting of hydrogen atom, methyl, ethyl, and cyclopropyl; R 4 is selected from the group consisting of hydrogen atom, straight or branched C1-C4 alkyl, straight or branched C1-C4 alkyl substituted with one or two halogen atoms, cyclopropyl and methylcyclopropyl; R 5 represents C1-C2 alkyl; k is an integer equal 1 or 2; I is an integer equal 1 or 2; m is an integer equal 0, 1 or 2; n is an integer 0 or 1 when X represents -NR4"or -CHN(R5) 2, wherein n is 1 only when m is 1; and n is 0 when X represents -0-; and acid addition salts thereof, can be useful as selective inhibitors of 5HT6 in the treatment of CNS diseases.

公开(公告)号：WO2019093547A1

公开(公告)日：2019-05-16

申请号：PCT/KR2017/012717

申请日：2017-11-10

申请人： 주식회사 진웅산업

发明人： 이응 ,  김동현 ,  이병윤 ,  이상진 ,  이지환 ,  조은상 ,  국창훈 ,  김대환 ,  황보선

IPC分类号： C07D471/04 ,  C07D401/04 ,  C07D401/10 ,  H01L51/00 ,  H01L51/50 ,  C09K11/06

CPC分类号： C07D401/04 ,  C07D401/10 ,  C07D471/04 ,  C09K11/06 ,  H01L51/00 ,  H01L51/50

摘要： 본 발명은 페난트롤린-안트라센 화합물 및 이를 하나 이상의 유기층에 포함함으로써 우수한 효율 특성을 나타내는 유기전기발광소자에 관한 것이다.

公开(公告)号：WO2019092752A2

公开(公告)日：2019-05-16

申请号：PCT/IN2018/050741

申请日：2018-11-13

申请人： AVRA LABORATORIES PVT. LTD.

发明人： ALLA, Venkata Rama Rao ,  RAMARAO, Chandrashekar ,  SHEWALKAR, Mukesh Padmakar ,  AMUDALA, Sampath

CPC分类号： C07D401/04 ,  A61P35/00

摘要： This invention discloses a novel pharmaceutical salt of Lenalidomide. More particularly, the invention discloses crystalline Trifluroacetic acid salt of Lenalidomide; polymorphic forms thereof and process for preparation thereof. The invention further discloses pharmaceutical composition comprising crystalline Trifluroacetic acid salt of Lenalidomide in association with one or more pharmaceutical excipients.

公开(公告)号：WO2019090081A1

公开(公告)日：2019-05-09

申请号：PCT/US2018/058963

申请日：2018-11-02

申请人： CALICO LIFE SCIENCES LLC ,  ABBVIE INC.

发明人： MARTIN, Kathleen, Ann ,  SIDRAUSKI, Carmela ,  FROST, Jennifer, M. ,  TONG, Yunsong ,  XU, Xiangdong ,  SHI, Lei ,  CHUNG, Seungwon ,  XIONG, Zhaoming ,  MURAUSKI, Kathleen ,  ZHANG, Qingwei, I. ,  BROWN, Brian, S. ,  DART, Michael, J.

IPC分类号： C07D207/26 ,  C07D209/46 ,  C07D207/273 ,  C07D233/32 ,  C07D239/88 ,  C07D239/96 ,  C07D263/20 ,  C07D265/10 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/04 ,  C07D413/12 ,  A61P3/00 ,  A61P19/00

CPC分类号： C07D207/273 ,  A61P3/00 ,  A61P19/00 ,  A61P21/00 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  C07D207/26 ,  C07D209/46 ,  C07D233/32 ,  C07D239/88 ,  C07D239/96 ,  C07D263/20 ,  C07D265/10 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/04 ,  C07D413/12

摘要： Provided herein are compounds of Formula (I) or Formula (II), compositions, and methods there of useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.